Dupilumab-Associated Mycosis Fungoides: Unmasked, Direct Effect, or a Lymphoid Reaction?

医学 病理 真菌病 免疫学 生物 淋巴系统 蕈样真菌病 免疫系统 淋巴瘤 病毒学
作者
Pauline Xu,Corey Georgesen,Matthew A. Lunning,Dinesh Pradhan
出处
期刊:American Journal of Dermatopathology [Lippincott Williams & Wilkins]
卷期号:48 (1): 80-80
标识
DOI:10.1097/dad.0000000000003423
摘要

ABSTRACT: Dupilumab, an interleukin (IL)-4 and IL-13 antagonist, is a biological agent approved in 2017 for the treatment of moderate-to-severe atopic dermatitis (AD). While dupilumab has proven revolutionary in managing AD, recent reports have emerged linking its use with the subsequent development of cutaneous T-cell lymphomas (CTCLs), including mycosis fungoides (MF) and Sézary syndrome. Between 2017 and 2023, a total of 178 cases of CTCLs were reportedly associated with dupilumab therapy for AD. The most common theory for this association is "unmasking," where patients were initially misdiagnosed with AD, failed first-line treatments and dupilumab, and later were correctly diagnosed with CTCLs. Another possibility is dupilumab might exacerbate or cause progression of preexisting CTCLs in a patient with concomitant AD. However, conversely, there is also the confounder of a false-positive diagnosis of MF after dupilumab that may overinflate the association data. It has also been reported that dupilumab can cause a reversible benign cutaneous lymphoid reaction that mimics early-stage MF both clinically and histologically, though data are sparse. As CTCL has been exclusively diagnosed in patients who received dupilumab for AD and not in patients who received dupilumab for other conditions such as asthma and since no increased incidence of noncutaneous lymphoma has been reported with dupilumab therapy, it appears unlikely that dupilumab causes or has an actual oncopathogenic effect in developing CTCL or transforming AD into lymphoma. However, this alarming observation emphasizes the need for further biological investigation in determining the mechanism by which dupilumab is associated with CTCL.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lily发布了新的文献求助10
刚刚
夏猫完成签到,获得积分10
1秒前
1秒前
zzq发布了新的文献求助10
1秒前
Xiaodan发布了新的文献求助10
2秒前
2秒前
伊莱克斯完成签到,获得积分10
3秒前
qqqqqq发布了新的文献求助10
3秒前
3秒前
huahua完成签到,获得积分10
3秒前
wjohn发布了新的文献求助20
4秒前
4秒前
5秒前
FashionBoy的应助被珍珠采纳,获得10
5秒前
浮云发布了新的文献求助20
5秒前
6秒前
fff完成签到 ,获得积分10
6秒前
su完成签到,获得积分10
6秒前
袋袋发布了新的文献求助10
6秒前
Ava的应助被noahxinny采纳,获得10
7秒前
星魂完成签到,获得积分10
8秒前
有缘完成签到,获得积分10
8秒前
跳跃以山的应助被醉熏的寄松采纳,获得10
9秒前
彭于晏的应助被重要的忆雪采纳,获得30
9秒前
10秒前
平生发布了新的文献求助10
10秒前
10秒前
啊熙完成签到,获得积分10
11秒前
cell发布了新的文献求助10
11秒前
苗条元霜发布了新的文献求助10
11秒前
12秒前
健身房之王完成签到,获得积分10
12秒前
zzq完成签到,获得积分10
12秒前
开心友儿完成签到,获得积分10
13秒前
小二郎的应助被启程牛牛采纳,获得10
13秒前
14秒前
xx完成签到,获得积分10
14秒前
swkxwdh给swkxwdh的求助进行了留言
15秒前
yebo完成签到,获得积分10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183241
求助须知:如何正确求助?哪些是违规求助? 9572493
关于积分的说明 21826218
捐赠科研通 7780115
什么是DOI,文献DOI怎么找? 3433982
关于科研通互助平台的介绍 2558103
邀请新用户注册赠送积分活动 2480192